Somayeh Ahmadiafshar1 
, Nowruz Delirezh * 2, Sanaz Sheikhzadeh3 , Rahim Hobbenaghi4 , Johan Garssen5
, Nowruz Delirezh * 2, Sanaz Sheikhzadeh3 , Rahim Hobbenaghi4 , Johan Garssen5
1- PhD Candidate of Immunology, Microbiology Department, School of Veterinary Medicine, Urmia University, Urmia, Iran
2- Professor of Immunology, Microbilogy Department, School of Veterinary Medicine, Urmia University, Urmia, Iran, Iran, Urmia city, 11km SERO Road. postal code:5756151818 , n.delirezh@urmia.ac.ir
3- Assistant Professor of Immunology, Microbilogy Department, School of Veterinary Medicine, Urmia University, Urmia, Iran
4- Associate Professor, Pathobiology Department, School of Veterinary Medicine, Urmia University, Urmia, Iran
5- Professor of Immunopharmacology, Utrecht University, Utrecht, Netherlands
2- Professor of Immunology, Microbilogy Department, School of Veterinary Medicine, Urmia University, Urmia, Iran, Iran, Urmia city, 11km SERO Road. postal code:5756151818 , n.delirezh@urmia.ac.ir
3- Assistant Professor of Immunology, Microbilogy Department, School of Veterinary Medicine, Urmia University, Urmia, Iran
4- Associate Professor, Pathobiology Department, School of Veterinary Medicine, Urmia University, Urmia, Iran
5- Professor of Immunopharmacology, Utrecht University, Utrecht, Netherlands
Abstract: (265 Views)
Nanotechnology mainly shows its inhibitory effect on the tumor microenvironment by modulating the immune suppression mechanism. Success in this field largely depends on the physicochemical characterization of nanoparticle vaccines. The goal of this study was to produce anti PD-L1 monoclonal antibody decorated nanoparticles containing linrodostat mesylate with desirable properties and to investigate their physicochemical characterization .
Nanoparticles were prepared using double emulsion-solvent_evaporation method. Size and morphology of the particles were investigated using the FESEM microscope method and polydispersity index and zeta potential of the particles using the DLS method, as well as release rate and encapsulation efficiency.
The research results showed that nanoparticles had a suitable uniform dispersion. In the group of nanoparticles containing linrodostat mesylate, the polydispersity index of particles was 0.06 and after the binding of anti-PDL1 monoclonal antibody was 0.24. All particles were spherical with a smooth surface. The ideal particle size for nanoparticles containing linrodostat mesylate was estimated to be 210.14 nm, and it was estimated to be about 270.35 nm after binding anti-PDL1 monoclonal antibody to nanoparticles. Binding of anti-PDL1 monoclonal antibody decreased the amount of encapsulated linrodostat mesylate. The release of linrodostat mesylate was biphasic, it has an initial phase with a steep slope and the next phase is a slow and controlled release.
The results showed that the vaccine based on nanoparticles produced by the double emulsion-solvent-evaporation method containing linrodostat mesylate and decorated with anti-PDL-1 monoclonal antibody has very suitable physicochemical characterization to be used as an immunotherapy vaccine.
Nanoparticles were prepared using double emulsion-solvent_evaporation method. Size and morphology of the particles were investigated using the FESEM microscope method and polydispersity index and zeta potential of the particles using the DLS method, as well as release rate and encapsulation efficiency.
The research results showed that nanoparticles had a suitable uniform dispersion. In the group of nanoparticles containing linrodostat mesylate, the polydispersity index of particles was 0.06 and after the binding of anti-PDL1 monoclonal antibody was 0.24. All particles were spherical with a smooth surface. The ideal particle size for nanoparticles containing linrodostat mesylate was estimated to be 210.14 nm, and it was estimated to be about 270.35 nm after binding anti-PDL1 monoclonal antibody to nanoparticles. Binding of anti-PDL1 monoclonal antibody decreased the amount of encapsulated linrodostat mesylate. The release of linrodostat mesylate was biphasic, it has an initial phase with a steep slope and the next phase is a slow and controlled release.
The results showed that the vaccine based on nanoparticles produced by the double emulsion-solvent-evaporation method containing linrodostat mesylate and decorated with anti-PDL-1 monoclonal antibody has very suitable physicochemical characterization to be used as an immunotherapy vaccine.
Article Type: Original Research |
Subject:
Nanotechnology
Received: 2023/02/10 | Accepted: 2023/07/12
Received: 2023/02/10 | Accepted: 2023/07/12
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |